Literature DB >> 9475193

Micropapillary serous carcinoma of the ovary: an immunohistochemical and mutational analysis of p53.

H Katabuchi1, H Tashiro, K R Cho, R J Kurman, L Hedrick Ellenson.   

Abstract

Micropapillary serous carcinoma (MPSC) has recently been described as a distinct ovarian neoplasm that shares histologic features with both serous borderline tumors (SBTs) and typical serous carcinomas of the ovary. To further define the relationship of MPSC to these two neoplasms, we evaluated all three tumor types for expression of the p53 protein and p53 gene mutations. The majority of MPSCs demonstrated positive, but only moderately intense, p53 immunostaining in >50% of the cells, whereas SBTs showed very weak staining in a small number of cells. In contrast, the majority of serous carcinomas displayed diffuse, very intense staining and those that did not stain completely lacked any staining for p53. This pattern of p53 immunostaining in MPSCs can be distinguished from the pattern observed in SBTs and in serous carcinomas. Both the MPSCs and the SBTs lacked p53 mutations in the cases analyzed, whereas all immunopositive serous carcinomas were found to have mutations in p53. In addition, one of the immunonegative cases of serous carcinoma had a frameshift mutation resulting in a truncated protein, providing a likely explanation for the lack of detectable p53 protein. These findings provide support for classifying MPSC as a distinct neoplasm of the ovary and suggest that increased expression of wild-type p53 may play a role in its pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9475193     DOI: 10.1097/00004347-199801000-00010

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  3 in total

1.  Diverse tumorigenic pathways in ovarian serous carcinoma.

Authors:  Gad Singer; Robert J Kurman; Hsueh-Wei Chang; Sarah K R Cho; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

2.  Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas.

Authors:  Carlos S Moreno; Lilya Matyunina; Erin B Dickerson; Nina Schubert; Nathan J Bowen; Sanjay Logani; Benedict B Benigno; John F McDonald
Journal:  PLoS One       Date:  2007-05-16       Impact factor: 3.240

Review 3.  The Putative Role of TP53 Alterations and p53 Expression in Borderline Ovarian Tumors - Correlation with Clinicopathological Features and Prognosis: A Mini-Review.

Authors:  Andrzej Semczuk; Marek Gogacz; Anna Semczuk-Sikora; Maciej Jóźwik; Tomasz Rechberger
Journal:  J Cancer       Date:  2017-08-22       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.